ArticleAmerican journal of cancer research2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Open access · greenAbstract read
In one paragraph
Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.Investigational new drugs · 2021Trial
- Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies.International journal of molecular sciences · 2026Review
- Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib.Drug design, development and therapy · 2026Review
- Hepatitis B virus core protein promotes liver cancer progression by stabilizing CANX and suppressing IRF7 transcription.Acta pharmacologica Sinica · 2025Article
- Therapeutic advances and application of PARP inhibitors in breast cancer.Translational oncology · 2025Review
- Development of a biomimetic nanoparticle platform for apigenin therapy in triple-negative breast cancer.Frontiers in oncology · 2025Article
- Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models.The Journal of clinical investigation · 2024Article
- Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.Journal of medical virology · 2023Article
- Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.Frontiers in genetics · 2023Review
- Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.Journal of biomedical science · 2022Review
- Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial.Translational lung cancer research · 2022Article
- Pharmacologic Induction of BRCAness inCancers · 2022Review
- MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.Genes · 2021Article
- Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.Frontiers in oncology · 2021Review
- Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.American journal of cancer research · 2021Article
- Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.Journal of translational medicine · 2020Article
- Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer.Cancer science · 2020Article
- Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.Signal transduction and targeted therapy · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Ye HanDepartment of Second Breast Surgery, China Medical University Affiliated Shengjing Hospital Shenyang, P. R. China.
Mei-Kuang ChenDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Hung-Ling WangGraduate Institute of Biomedical Sciences, College of Medicine, China Medical University Taichung 40402, Taiwan.
Jennifer L HsuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Chia-Wei LiDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Yu-Yi ChuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Chun-Xiao LiuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Lei NieDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Li-Chuan ChanDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Clinton YamDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Shao-Chun WangGraduate Institute of Biomedical Sciences, College of Medicine, China Medical University Taichung 40402, Taiwan.
Gui-Jin HeDepartment of Second Breast Surgery, China Medical University Affiliated Shengjing Hospital Shenyang, P. R. China.
Gabriel N HortobagyiDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Xiao-Dong TanDepartment of Thyroid and Pancreatic Surgery, China Medical University Affiliated Shengjing Hospital Shenyang, P. R. China.
Mien-Chie HungDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MMechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its ResistanceU01CA201777 · NCI · MASIMO CORPORATION · PI NAULI, SURYA, SHARMA, VIKRANT · 2016 to 2020
$2.4MRational Combination Therapy with PARP Inhibitors in Triple Negative Breast CancerR01CA211615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, LIUQING · 2017 to 2021
$2.1MTraining Grant in Cancer BiologyT32CA186892 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2016 to 2020
$1.1MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA211615NCI NIH HHS T32 CA186892NCI NIH HHS U01 CA201777
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are promising targeted therapeutics for breast and ovarian cancers bearing a germline
Indexed as
high-grade serous ovarian cancerMETPARPresistanceSHR-3162Targeted therapytriple-negative breast cancer
Identifiers
PMID
30949414PMC
PMC6448061OpenAlex
W2981086035What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.